Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA Adverse Event Reporting System.

CONCLUSION: When prescribing PD-1 inhibitors, physicians should monitor closely for symptoms of bullous pemphigoid. PMID: 31088310 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research